Domestic first imitation! Nanjing Zhengtianqing new product Omeishatan ammonia chloride flat tablets on the market

Data monitoring, December 14, Nanjing Zhengda Tianqing cardiovascular field key products Tianshuping ® (Umesatan ammonia chloride tablets) to obtain the State Drug Administration's pharmaceutical production approval, the product belongs to the chemical medicine 4 categories, as as through the quality and efficacy of consistent evaluation.
: Zhengda Qing Omeshatan ammonia chloride tablet review time axis Omeshatan is suitable for the treatment of primary hypertension, especially for moderate to severe hypertension and single-drug treatment of patients who do not reach the target.
ARB Umesatan as the latest generation of ARB drugs, because of its unique "2046" structure, with a more powerful, long-lasting, stable anti-pressure effect, its combination with CCB ammonia chloride can be called a strong combination of anti-pressure treatment model, is able to achieve strong buck, high compliance rate and good tolerance of clinical preferred treatment.
Tu: The powerful antihypertensive effect of Omeshatan ammonia chloride tablets has been consistently confirmed in patients with simple hypertension, patients with hypertension at all levels and simple contractionary hypertension (ISH), special groups of hypertension and patients with hypertension in China and Asia.
, whether it is single-drug application or joint application, clinical applications in the world and even in China have made great progress, showing stronger anti-pressure advantages and good target organ protection.
2018 by NMPA for the real estate of the original research drug, Omeshatan ammonia chloride tablets of The First Third Common Pharmaceuticals (Shanghai) Co., Ltd. were approved for listing by NMPA.
this time is sunny Omeshatan ammonia chloride flat tablets were approved, become the first imitation in China, will certainly benefit china's hypertension patients to a greater extent.
data show that India's Arabindo Pharmaceuticals Class 5.2 drugs have also been listed, and 3 other enterprises (Shan Eastern Europe China Pharmaceuticals, Castrol (Hunan) Pharmaceutical Technology, Jiangsu Hengrui Pharmaceuticals shares) have been approved clinically.
。